This observational study is looking at the gut microbiome (the community of bacteria and other tiny organisms in your intestines) in people with solid cancers who are receiving immunotherapy. Specifically, researchers want to understand how the gut microbiome of patients receiving PD-1 or PD-L1 inhibitors (types of immunotherapy) relates to their treatment response. You may be able to join if you are between 35 and 75 years old, have a nonresectable or metastatic solid cancer, and have been receiving PD-1 or PD-L1 inhibitor immunotherapy for at least 3 months but less than 24 months. The main goal is to describe the types of bacteria in your gut using molecular methods at the start of the study. The study plans to enroll 16 participants, but its current status is unclear.

Study design

This is an observational study, meaning researchers will collect information without giving you a specific intervention. It plans to enroll 16 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, characterizing the fecal microbiome, is measured at baseline (the start of the study).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.